good

good

n

i

c

e

Had hoped to hear a better description of the types of trials and more about the Regulators' logic in deciding what trials a drug must have - PK for ANDA? BE for ANDA? P1 and P3 for 505B2? Does PK=P1? These topics are useful. Need to define these options and explain the reason for using them for different scenarios. That's part of what I expected from Drug Development.

The lecture style of second half was difficult. More structure, clear pronunciation, less random thoughts about unexplained topics.

Phase 1 was explained nicely. But phase 2 description was unclear with some diagrams with not much context and a lot of acronyms thrown around. Did not learn a lot about phase 3 either. The presentation slides were very busy like the previous course.

I felt like the lectures were not so organized as far as their material is concerned. I also found the overall course more "business-oriented" than actually educational.

Okayish. I wouldn't recommend this. If you're really passionate about Drug Development and it's clinical aspects, try and find better courses.

The course was not structured as an online course. the slides were quite boring and some of the speakers were not enthusiastic

Outdated series of classes that offer no real learning opportunities.

Presentation slides and sound quality is at its lowest.

The course is not prepared for online course

A lot too much bla bla on the Phase iv part

I only looked at the slides, as I wanted to confirm, what I read in some of the reviews. A standard issue on Coursera is, that material is not maintained and updated. I have worked in the pharmaceutical industry for more than 15 years now and everything is constantly evolving. The world of 2013 is not the world of 2020 and course material should e updated regularly.

The data shown in the lecture and even the lecture itself is dated back to 2012. Kindly upload an updated lecture with new rules, recent data, recent examples. It would be of great help.

Nice very important

Thank u so much